Drug Approval | October 16, 2024
Shilpa Medicare’s CDMO customer gets fast-track designation for its investigational drug candidate
GBM affects nearly 13,000 patients annually in the US and approximately 300,000 globally
GBM affects nearly 13,000 patients annually in the US and approximately 300,000 globally
He will join in place of Anil Arora, current President- Formulations Operations who will be superannuating in November, 2024
Declan brings over 25 years of expertise in the pharmaceutical and biotech sectors
The new facility uses the latest mammalian systems and single-use technology, including a production line with eight 2,000 L bioreactors
Strokes are affecting approximately 1.8 million people annually
Wockhardt's yet another novel antibiotic Miqnaf receives favourable recommendation from Subject Expert Committee of CDSCO
The partnership marks a pivotal step towards developing new therapies for combating Sickle Cell Disease
The GMP certificate will allow the manufacturing site in Hervás, Cáceres to manufacture active ingredients for the pharmaceutical industry that is based on medicinal plants
HYMPAVZI’s approval is based on Phase 3 study results demonstrating substantial bleed reduction compared to routine prophylaxis
Paliperidone extended-release tablets will be produced at the Group’s manufacturing site at SEZ, Ahmedabad
Subscribe To Our Newsletter & Stay Updated
